• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Inovio snags $56m award for Lassa fever, MERS vaccines

April 11, 2018 By Sarah Faulkner

Inovio PharmaceuticalsInovio Pharmaceuticals (NSDQ:INO) inked a $56 million partnership with the Coalition for Epidemic Preparedness Innovations to develop vaccine candidates against Lassa fever and middle east respiratory syndrome.

According to the terms of the deal, CEPI is slated to support Inovio’s preclinical and clinical efforts through to Phase II trials of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The agreement also includes options to establish stockpiles of both vaccines, the companies reported.

“Epidemics don’t respect borders; they destroy lives and devastate economies and we need to move swiftly to prepare for them. Partnering with Inovio is a considerable move forward for CEPI’s vaccine portfolio and developing a global insurance policy against these diseases,” CEPI’s chief executive, Richard Hatchett, said in prepared remarks.

“The Inovio/CEPI partnership demonstrates the confidence of both organizations in Inovio’s DNA vaccine platform to rapidly produce countermeasures against emerging viral threats potentially protecting large populations from a pandemic,” Inovio president & CEO Dr. J. Joseph Kim added. “A key demonstration of such capabilities was that Inovio was the first organization to develop, manufacture and report positive human data from a Zika vaccine in less than seven months – when traditional vaccines take several years to reach this point. We look forward to addressing the global health challenges of emerging infectious diseases.”

In a first-in-human Phase I trial of its MERS vaccine, Inovio reported that 92% of participants had high levels of binding antibodies and all but one vaccinated participant generated a T-cell or antibody response against the vaccine. In a study of its Lassa fever vaccine, Inovio touted that the product provided 100% protection for non-human primates given a lethal dose of the virus.

INO shares were up 4.8% in mid-afternoon activity today, trading at $4.99 apiece.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Inovio Pharmaceuticals

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS